Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders

[91] Karran E(2016)Role of the tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms Sci Rep 135 1247-10875

[92] Mercken M(2012)Glycation alter the process of tau phosphorylation to change Tau isoforms aggregation property Brain 5 734-1031

[93] De SB(2013)Tissue transglutaminase in Alzheimer’s disease: involvement in pathogenesis and its potential as a therapeutic target EMBO Mol Med 142 8979-828

[94] Myers A(2017)A phase iia randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer’s disease J Neurochem 55 1-10

[95] McGonigle P(2012)Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease J Med Chem 4 10862-201

[96] Bloom GS(2016)MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice Acta Neuropathol Commun 290 22-303

[97] Deture MA(2015)[P4–039]: Pan-tau antibody Biib076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study J Biol Chem 7 1019-232

[98] Dickson DW(2019)Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease Acta Neuropathol Commun 377 814-833

[99] Chen GF(2011)Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression Lancet 12 1-2024

[100] Xu TH(2015)Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody Curr Alzheimer Res 5 192-6

[91] Karran E(2016)Role of the tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms Sci Rep 135 1247-10875

[92] Mercken M(2012)Glycation alter the process of tau phosphorylation to change Tau isoforms aggregation property Brain 5 734-1031

[93] De SB(2013)Tissue transglutaminase in Alzheimer’s disease: involvement in pathogenesis and its potential as a therapeutic target EMBO Mol Med 142 8979-828

[94] Myers A(2017)A phase iia randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer’s disease J Neurochem 55 1-10

[95] McGonigle P(2012)Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease J Med Chem 4 10862-201

[96] Bloom GS(2016)MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice Acta Neuropathol Commun 290 22-303

[97] Deture MA(2015)[P4–039]: Pan-tau antibody Biib076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study J Biol Chem 7 1019-232

[98] Dickson DW(2019)Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease Acta Neuropathol Commun 377 814-833

[99] Chen GF(2011)Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression Lancet 12 1-2024

[100] Xu TH(2015)Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody Curr Alzheimer Res 5 192-6